Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-3,754
Closed -$34.7K 710
2019
Q3
$34.7K Buy
3,754
+3,000
+398% +$38.7K 0.01% 383
2019
Q2
$13.7K Sell
754
-2,725
-78% -$41.9K ﹤0.01% 442
2019
Q1
$48.7K Sell
3,479
-3,423
-50% -$50.2K 0.01% 341
2018
Q4
$92.4K Sell
6,902
-13,288
-66% -$195K 0.02% 326
2018
Q3
$319K Buy
20,190
+747
+4% +$11.6K 0.06% 196
2018
Q2
$271K Sell
19,443
-13,564
-41% -$265K 0.05% 230
2018
Q1
$709K Sell
33,007
-3,612
-10% -$83.7K 0.14% 146
2017
Q4
$839K Buy
36,619
+353
+1% +$8.1K 0.14% 112
2017
Q3
$808K Buy
36,266
+5,121
+16% +$106K 0.15% 93
2017
Q2
$682K Buy
31,145
+4,309
+16% +$104K 0.15% 109
2017
Q1
$651K Sell
26,836
-44,429
-62% -$957K 0.15% 120
2016
Q4
$1.18M Buy
71,265
+7,119
+11% +$122K 0.23% 81
2016
Q3
$1.17M Sell
64,146
-57,091
-47% -$1.03M 0.18% 89
2016
Q2
$2.33M Sell
121,237
-25,894
-18% -$515K 0.38% 51
2016
Q1
$2.63M Buy
147,131
+267
+0.2% +$4.43K 0.35% 53
2015
Q4
$2.31M Sell
146,864
-5,875
-4% -$107K 0.32% 55
2015
Q3
$2.33M Buy
152,739
+76,015
+99% +$1.7M 0.29% 61
2015
Q2
$2.1M Sell
76,724
-3,428
-4% -$100K 0.23% 63
2015
Q1
$2.2M Buy
80,152
+29,785
+59% +$768K 0.24% 59
2014
Q4
$1.33M Buy
+50,367
New +$1.56M 0.18% 87

Other funds holding YPF

Exane Derivatives's YPF Position: Q4 2019 in Review

Exane Derivatives sold out of YPF (YPF) in Q4 2019, closing a stake of 3,754 shares — an estimated $34.7K sold.

Exane Derivatives first reported a position in YPF in Q4 2014 and held it in 20 quarters. The position peaked at $2.63M in Q1 2016. 127 funds tracked by Wall St. Rank hold YPF as of Q4 2019.

  • Exane Derivatives reported no remaining YPF position as of Q4 2019 after selling out during the quarter.
  • Exane Derivatives sold 3,754 YPF shares in Q4 2019, an estimated $34.7K.
  • Exane Derivatives first reported a position in YPF in Q4 2014 and held it in 20 quarters.
  • Exane Derivatives's YPF position peaked at $2.63M in Q1 2016.
  • 127 funds tracked by Wall St. Rank held YPF as of Q4 2019.

Based on Exane Derivatives's 13F filing for Q4 2019, filed 22 Jan 2020.